Showing results (321-330 of 363) with videos related to

Sort By:
Pageof 37
Cancer Cell|April 21, 2023
Transcriptional-translational conflict is a barrier to cellular transformation and cancer progressionSujata Jana, Sandipan Brahma, Sonali Arora, et al.
BJU International|September 27, 2020
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinomaDavid D'Andrea, Surena Matin, Peter C Black, et al.
World Journal of Urology|February 10, 2022
Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancerLuca Afferi, Chiara Lonati, Francesco Montorsi, et al.
BJU International|July 9, 2025
Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancerMarkus von Deimling, Marc Furrer, Alberto Bianchi, et al.
European Urology Open Science|May 15, 2023
Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder CancerMarkus von Deimling, Laura S Mertens, Bas W G van Rhijn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2018
Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder CancerRoland Seiler, Ewan A Gibb, Natalie Q Wang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 3, 2025
Cross-platform methylation-based site of origin classification for squamous cell carcinomasAllen W Zhang, Vahid Akbari, Andrew Galbraith, et al.
The Journal of Urology|August 27, 2021
Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder CancerDavid D'Andrea, Peter C Black, Homayoun Zargar, et al.
BJU International|October 31, 2023
Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancerMarkus von Deimling, Marc Furrer, Laura S Mertens, et al.
BJU International|November 5, 2020
Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosisFrancesco Soria, Peter C Black, Adrian S Fairey, et al.
Pageof 37